Trial to evaluate the effectiveness of the Dream Completion Technique

  • Research type

    Research Study

  • Full title

    A Randomised Control Trial to evaluate the effectiveness of a psychological intervention for treating nightmares within a UK Primary Care NHS IAPT Service

  • IRAS ID

    300024

  • Contact name

    Neil Fallon

  • Contact email

    neil.fallon@nhs.net

  • Sponsor organisation

    Pennine Care NHS Foundation Trust

  • Clinicaltrials.gov Identifier

    2021-005014-33, EudraCT Number

  • Duration of Study in the UK

    2 years, 0 months, 0 days

  • Research summary

    Nightmares are a very common symptom for individuals who have experienced psychological trauma, and they can have a significant impact on sleep quality and daily functioning. Nightmares can also continue many years after the original traumatic event, although it is also possible to have nightmares with no associated trauma. There are no specific nightmare treatment approaches routinely used within IAPT services, although technique such as Image Rehearsal Therapy have previously been evaluated in the US and Europe.

    The Dream Completion Technique (DCT) is a brief technique for teaching patients how to stop nightmares and improve sleep and has advantages over treatments such as Image Rehearsal. It has previously been evaluated in group session format with UK military veterans. The core concept of the DCT approach is that content of dreams may be influenced by conscious thoughts and imagery, and that this can be used to permanently end a nightmare. By using the technique, sleep can be improved and previous studies have indicated a positive impact on daily functioning and PTSD symptoms.

    A Randomised Control Trial at the Oldham Healthy Minds IAPT service is proposed to determine how effective the intervention is, and whether there is any impact on the duration and outcomes of standard therapy. For those patients experiencing at least weekly nightmares who have consented to participate, half will be randomly allocated to receive standard therapy care and the other half of the participants will receive standard care plus the DCT in the first treatment session. Standard IAPT measures will be used before, during and 3-months after completion of treatment, along with a validated measure to assess frequency and severity of nightmares and sleep disturbance called the Nightmare Assessment Scale. The trial will last 2 years and include a minimum of 60 participants experiencing weekly nightmares.

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    21/SC/0335

  • Date of REC Opinion

    4 Nov 2021

  • REC opinion

    Further Information Favourable Opinion